S B Margolin
Overview
Explore the profile of S B Margolin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
SHETLAR M, Shetlar D, Bloom R, SHETLAR C, Margolin S
J Lab Clin Med
. 1998 Dec;
132(6):491-6.
PMID: 9851739
The experimental drug pirfenidone (PFD) has been evaluated as an inhibitor of keloid proliferation and compared with triamcinolone (TAC) injections by studying the involution of active human keloid implants in...
12.
Kaneko M, Inoue H, Nakazawa R, Azuma N, Suzuki M, Yamauchi S, et al.
Clin Exp Immunol
. 1998 Aug;
113(1):72-6.
PMID: 9697986
Pirfenidone has been shown to modify some cytokine regulatory actions and inhibit fibroblast biochemical reactions resulting in inhibition of proliferation and collagen matrix synthesis by fibroblast. We have investigated the...
13.
Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin S, Kurokawa K
Kidney Int
. 1998 Jul;
54(1):99-109.
PMID: 9648068
Background: Pirfenidone (PFD) is a novel anti-fibrotic agent that can prevent and even reverse extracellular matrix accumulation in several organs, as shown by experimental and clinical studies. Unilateral ureteral obstruction...
14.
Iyer S, Margolin S, Hyde D, Giri S
Exp Lung Res
. 1998 Feb;
24(1):119-32.
PMID: 9457473
Interstitial lung fibrosis (ILF) is a life-threatening disease which has no known drug for prevention and cure. In the present study, we evaluated the antifibrotic potential of pirfenidone (PD) (5-methyl-1-phenyl-2-(1H)-pyridone)...
15.
Lee B, Margolin S, Nowak R
J Clin Endocrinol Metab
. 1998 Jan;
83(1):219-23.
PMID: 9435445
There are currently no effective, long-term drug therapies for the treatment of leiomyomas. Pirfenidone (Marnac, Inc.) is an antifibrotic agent that is being tested for use in patients with pulmonary...
16.
Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, et al.
Kidney Int Suppl
. 1998 Jan;
63:S239-43.
PMID: 9407470
Pirfenidone (PFD) is a new compound that prevents and even reverses the extracellular matrix accumulation in several organs as shown by experimental and clinical studies. In the present study, we...
17.
Kehrer J, Margolin S
Toxicol Lett
. 1997 Feb;
90(2-3):125-32.
PMID: 9067480
The deposition of excess or abnormal collagen characteristic of pulmonary fibrosis can disrupt gas exchange resulting in severe respiratory impairment. There currently are no effective pharmacologic agents available that inhibit...
18.
Taniyama M, Ohbayashi S, Narita M, Nakazawa R, Hasegawa S, Azuma N, et al.
Eur J Clin Pharmacol
. 1997 Jan;
52(1):77-8.
PMID: 9143872
No abstract available.
19.
Iyer S, Wild J, Schiedt M, Hyde D, Margolin S, Giri S
J Lab Clin Med
. 1995 Jun;
125(6):779-85.
PMID: 7539478
There are no clinically efficacious drugs available for preventing the development of pulmonary fibrosis (PF). In the present study, we tested the antifibrotic potential of pirfenidone (PD) in the bleomycin...
20.